Skip to content
DataLookout
Menu

NCT07926893

Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Incidence of dose limiting toxicities (DLT)
Timeframe: From baseline, up to completion of cycle 3 (cycle length = 21 days)
Incidence of adverse events
Timeframe: Up to 1 year

Secondary (7)

Overall response
Complete response
Time to response
Sustained response
Duration of response
Show 2 moreShow less
Progression free survival
Overall survival

Arms and interventions

Treatment (cosibelimab and lenalidomide)Experimental

Patients receive cosibelimab IV over 1 hour on day 1 and lenalidomide PO QD on days 1-14 of each cycle. Cycles repeat every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan with or without PET scan at baseline and may undergo CT scan with or without PET scan throughout the trial. Patients undergo skin biopsy and blood sample collection throughout the study.

Procedures: Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Skin Biopsy

Drugs: Cosibelimab, Lenalidomide

Other: Questionnaire Administration

Sites

1 site in 1 country

  • City of Hope Medical CenterDuarte, California, United States